Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): A population-based study in the South of Switzerland, 1999-2005

Histology and Histopathology

Volumn 23, Issue 11, 2008, Pages 1379-1386

  Mazzola, Paola ^a   Spitale, Alessandra ^a   Banfi, Sara ^a   Mazzucchelli, Luca ^a   Frattini, Milo ^a   Bordoni, Andrea ^a  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

C kit; Cancer registry; Epidemiology; Gastrointestinal stromal tumors; PDGFRA

Indexed keywords

DNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; RISK ASSESSMENT; SWITZERLAND; EXON; GENE EXPRESSION REGULATION; GENETICS; HEALTH SURVEY; MIDDLE AGED; MUTATION; REGISTER; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTATION; POPULATION SURVEILLANCE; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REGISTRIES; RETROSPECTIVE STUDIES; SWITZERLAND;

EID: 58149134864     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Andersson J., Bümming P., Meis-Kindblom J.M., Sihto H., Nupponen N., Joensuu H., Odén A., Gustavsson B., Kindblom L-G. and Nilsson B. (2006). Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130, 1573-1581.
2. Corless C.L., Fletcher J.A. and Heinrich M.C. (2004). Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22, 3813-3825.
3. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., Shiraga S., Bainbridge T., Morich J. and Heinrich M.C. (2005). PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23, 5357-5364.
4. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D. and Joensuu H. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480.
5. Esteve J., Benhamou E. and Raymond L. (1994). Statistical methods in cancer research. Vol. 4. IARC Scientific Publications. World Health Organization. Lyon.
6. Fletcher C.D.M., Berman J.J., Corless C.L., Gorstein F., Lasota J., Longley B.J., Miettinen M., O'Leary T.J., Remotti H., Rubin B.P., Shmookler B., Sobin L.H. and Weiss S.W. (2002). Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. 33, 459-465.
7. Fritz A., Percy C., Jack A., Shanmugaratnam K., Sobin L., Parkin D.M. and Whelan S. (2000). International Classification of Diseases for Oncology. 3rd ed. World Health Organization. Genève.
8. Gilbertson R.J., Langdon J.A., Hollander A., Hernan R., Hogg T.L., Gajjar A., Fuller C. and Cliffford S.C. (2006). Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur. J. Cancer. 42, 646-649.
9. Goettsch W.G., Bos S.D., Breekveldt-Postma N., Casparie M., Herings R.M. and Hogendoorn P.C. (2005). Incidence of gastrointestinal stromal tumors is underestimated: results of a nation-wide study. Eur. J. Cancer. 41, 2868-2872.
10. Graadt van Roggen J.F., van Velthuysen M.L.F. and Hogendoorn P.C.W. (2001). The histopathological differential diagnosis of gastrointestinal stromal tumors. J. Clin. Pathol. 54, 96-103.
11. Hirota S., Isozaki H., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Muhammad Tunio G., Matsuzawa Y., Kanakura Y., Shinomura Y. and Kitamura Y. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580.
12. Jensen O.M., Parkin D.M., Maclennan R. and Muir C.S. and Skeet R.G. (1991). Cancer registration principles and methods. IARC Scientific Publications. Lyon.
13. Joensuu H. (2006). Gatrointestinal stromal tumor (GIST). Ann. Oncol. 17, 280-286.
14. Kindblom L.G., Remotti H.E., Aldenborg F. and Meis-Kindblom J.M. (1998). Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol. 152, 1259-1269.
15. Miettinen M. and Lasota J. (2001). Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchow Arch. 438, 1-12.
16. Miettinen M., Majidi M. and Lasota J. (2002). Pathology and diagnostic criteria of gastrointestinal stromal tumors (GIST): a review. Eur. J. Carcer 38(suppl), 39-51.
17. Miselli F.C., Casieri P., Negri T., Orsenigo M., Lagonigro M.S., Gronchi A., Fiore M., Casali P.G., Bertulli R., Carbone A., Pierotti M.A., Tamborini E. and Pilotti S. (2007). C-kit/PDGFRA gene status alterations possibly related to primari imatinib resistance in gastrointestinal stromal tumors. Clin. Cancer. Res. 13, 2369-2377.
18. Mucciarini C., Rossi G., Bertolini F., Valli R., Cirilli C., Rashid I., Marcheselli L., Luppi G. and Federico M. (2007). Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer. 7, 230.
19. Nilsson B., Bumming P., Meis-Kindblom J.M., Oden A., Dortok A., Gustavsson B., Sablinska K. and Kidblom L.G. (2005). Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. A population-based study in Western Sweden. Cancer 103, 821-829.
20. Penzel R., Aulmann S., Moock M., Schwarzbach M., Rieker R.J. and Mechtersheimer G. (2005). The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumors is site and phenotype associated. J. Clin. Pathol. 58, 634-639.
21. Rubin B.P. (2006). Gastrointestinal stromal tumors: an update. Histopathology 48, 83-96.
22. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., Hibbard M.K., Chen C.J., Xiao S., Tuveson D.A., Demetri G.D., Fletcher C.D. and Fletcher J.A. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61, 8118-8121.
23. Rubió J., Marcos-Gragera R., Ortiz M.R., Miró J., Vilardell L., Gironès J., Hernandez-Yagüe X., Codina-Cazador A., Bernadó L., Izquierdo A. and Colomer R. (2007). Population-based incidence and survival of gastrointestinal stromal tumors (GIST) in Girona, Spain. Eur. J. Cancer. 43, 144-148
24. Steigen S.E. and Eide T.J. (2006). Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS 114, 192-200.
25. Steigen S.E., Eide T.J., Wasag B., Lasota J. and Miettinen M. (2007). Mutations in gastrointestinal stromal tumors - a population-based study from Northern Norway. APMIS 115, 289-298.
26. Tryggvason G., Gislason H.G., Magnusson M.K. and Jonasson J.G. (2005). Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int. J. Cancer 117, 289-293.
27. Yamanda T. (2003). Textbook of gastroenterology. 4th ed. Lippincott Williams & Wilkins. Philadelphia.